281 related articles for article (PubMed ID: 32557206)
1. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.
Comel AC; Mosaner W; Bragantini D; Lanzafame M
Infection; 2021 Feb; 49(1):195-196. PubMed ID: 32557206
[No Abstract] [Full Text] [Related]
2. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Zhao H; Zhu Q; Zhang C; Li J; Wei M; Qin Y; Chen G; Wang K; Yu J; Wu Z; Chen X; Wang G
Biomed Pharmacother; 2021 Jan; 133():110825. PubMed ID: 33378989
[TBL] [Abstract][Full Text] [Related]
4. An EUA for bamlanivimab and etesevimab for COVID-19.
Med Lett Drugs Ther; 2021 Apr; 63(1621):49-50. PubMed ID: 33830966
[No Abstract] [Full Text] [Related]
5. Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab.
Salvati L; Occhipinti M; Gori L; Ciani L; Mazzoni A; Maggi L; Capone M; Parronchi P; Liotta F; Miele V; Annunziato F; Lavorini F; Cosmi L
Immunol Lett; 2020 Dec; 228():122-128. PubMed ID: 33161002
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?
Buryachkovskaya L; Lomakin N; Melkumyants A; Docenko J; Serebruany V
Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):e81-e82. PubMed ID: 34185077
[No Abstract] [Full Text] [Related]
7. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Samaee H; Mohsenzadegan M; Ala S; Maroufi SS; Moradimajd P
Int Immunopharmacol; 2020 Dec; 89(Pt A):107018. PubMed ID: 33045577
[TBL] [Abstract][Full Text] [Related]
9. Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report.
Witting C; Quaggin-Smith J; Mylvaganam R; Peigh G; Angarone M; Flaherty JD
Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115272. PubMed ID: 33388572
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy?
Giglia M; Beci G; Rosselli Del Turco E; Guardigni V; Amedeo A; Cucchetto G; Verucchi G; Cipolli M; Calza L; Viale P
Monaldi Arch Chest Dis; 2020 Dec; 90(4):. PubMed ID: 33372741
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy.
Masci GM; Iafrate F; Ciccarelli F; Pambianchi G; Panebianco V; Pasculli P; Ciardi MR; Mastroianni CM; Ricci P; Catalano C; Francone M
Radiol Med; 2021 Sep; 126(9):1170-1180. PubMed ID: 34089436
[TBL] [Abstract][Full Text] [Related]
12. An EUA for sotrovimab for treatment of COVID-19.
Med Lett Drugs Ther; 2021 Jun; 63(1627):97-xx98. PubMed ID: 34181630
[No Abstract] [Full Text] [Related]
13. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety.
Hill JA; Menon MP; Dhanireddy S; Wurfel MM; Green M; Jain R; Chan JD; Huang J; Bethune D; Turtle C; Johnston C; Xie H; Leisenring WM; Nina Kim H; Cheng GS
J Med Virol; 2021 Apr; 93(4):2270-2280. PubMed ID: 33200828
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
[TBL] [Abstract][Full Text] [Related]
15. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
Ulhaq ZS; Soraya GV
Med Clin (Barc); 2020 Dec; 155(12):548-556. PubMed ID: 32950258
[No Abstract] [Full Text] [Related]
16. A case report of super responder of critical COVID-19 pneumonia.
Kishaba T; Maeda A; Fukuoka S; Imai T; Takakura S; Yokoyama S; Shiiki S; Narita M; Nabeya D; Nagano H
J Med Invest; 2021; 68(1.2):192-195. PubMed ID: 33994470
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
[No Abstract] [Full Text] [Related]
18. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
Potere N; Di Nisio M; Cibelli D; Scurti R; Frattari A; Porreca E; Abbate A; Parruti G
Ann Rheum Dis; 2021 Feb; 80(2):1-2. PubMed ID: 32647027
[No Abstract] [Full Text] [Related]
19. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C;
J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677
[TBL] [Abstract][Full Text] [Related]
20. [COVID-19: Still a place for tocilizumab?].
Richier Q; Plaçais L; Lacombe K; Hermine O
Rev Med Interne; 2021 Feb; 42(2):73-78. PubMed ID: 33288230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
